Venture Life Group PLC Increased distribution of UltraDEX in Boots, UK (6319R)
June 18 2018 - 2:00AM
UK Regulatory
TIDMVLG
RNS Number : 6319R
Venture Life Group PLC
18 June 2018
Venture Life Group plc
("Venture Life" or the "Company")
Increased distribution of UltraDEX in Boots Chemists, UK
Venture Life (AIM: VLG), the international consumer self-care
company focused on developing, manufacturing and commercialising
products for the self-care market, announces increased distribution
in the UK with Boots for its UltraDEX range.
The Company announces that its listings of UltraDEX products
with Boots in the UK will increase by 46% from July onwards, its
highest recorded level in Boots, and added to all current existing
listings in Boots and other stores this creates the highest level
of total listings in the UK market since the brand launched 25
years ago. In addition to increasing the presence of some of the
existing products, Boots will be launching both of the newly
developed UltraDEX products: UltraDEX One GO(TM), and the new
UltraDEX Fresh Breath Essential Kit.
UltraDEX One GO(TM), which also recently launched in all 793
Superdrug stores, is an innovative new product that delivers the
UltraDEX fresh mint mouthwash in the form of single use sachets,
for convenient on-the-go use. The UltraDEX Fresh Breath Essential
Kit comprises four different UltraDEX products in one package,
designed to introduce the customer to a daily regimen of fresh
breath and oral care.
Boots is the UK's leading pharmacy-led health and beauty
retailer with around 2,500 stores nationwide. These increases in
distribution will add a further 3,686 new points of distribution
for UltraDEX in Boots stores from July 2018. These additions,
combined with others already gained in the last 12 months in Boots
and other stores mean that the UltraDEX brand now has a total of
over 18,800 points of distribution in the UK, its highest level
ever nationally, and a 49% increase over its position in July
2017.
In support of this launch, promotion of the new product UltraDEX
One GO(TM) via above the line advertising will appear on the London
Underground platform posters from mid-June and will run for two
weeks.
In addition, the UltraDEX Sensitive range has been granted a
patent in Canada. This new patent adds to the existing patents
granted for this innovative range in eight other countries
including USA, UK, Japan and Australia.
Commenting Chief Executive Officer, Jerry Randall, said: "These
additional listings in Boots are a tremendous testament to the
strength of the UltraDEX range in the UK and its increasingly
prominent position in one of the largest pharmacy chains
countrywide. These listings have resulted in a 46% increase in the
UltraDEX presence in Boots. Over the last 12 months, including this
increase announced today, we have seen a 49% increase in our
overall UK pharmacy and retail store listings for the range, taking
it to the highest level ever for the brand.
"The acceptance of both of our new products into Boots
demonstrates our ability to develop new innovative lines that gain
rapid acceptance in key retailers. I am delighted that we continue
to deliver on the strategic objectives we set out when acquiring
UltraDEX, and I am confident that we can deliver similar results
with other brands. The UK is not, however, the sole focus for
UltraDEX and we have now partnered the range internationally in
nine countries since acquisition, including three of the four main
countries in the EU. We have also widened the patent estate over
the UltraDEX Sensitive range, where the patent has now been
approved in Canada, meaning this patent now covers a total of nine
countries worldwide. As a Company we are excited about the future
of UltraDEX and the broader territories we can continue to target
with this product range."
For further information please contact:
+44 (0) 1344
Venture Life Group PLC 742870
Jerry Randall, Chief Executive Officer
Adrian Crockett, Chief Financial Officer
Northland Capital Partners Limited (Nominated Adviser +44 (0) 20 3861
and Joint Broker) 6625
Matthew Johnson / Edward Hutton (Corporate Finance)
John Howes / Vadim Alexandre (Corporate Broking)
+44 (0) 20 3621
Turner Pope Investments (TPI) Ltd (Joint Broker) 4120
James Pope / Ben Turner
Walbrook PR venturelife@walbrookpr.com or +
44 (0) 20 7933 8780
Anna Dunphy /Paul McManus +44 (0) 7876 741 001 / +44 (0) 7980
541 893
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the ageing population. The Group's product portfolio includes
some key products such as the UltraDEX oral care products range,
food supplements for lowering cholesterol and maintaining brain
function, medical devices for women's intimate healthcare and
haemorrhoids and dermo-cosmetics for addressing the signs of
ageing.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies supplied by the Group's international distribution
partners.
Through its Development & Manufacturing business in Italy,
Biokosmes, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic
sectors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCKDLBFVQFLBBL
(END) Dow Jones Newswires
June 18, 2018 02:00 ET (06:00 GMT)
Venture Life (LSE:VLG)
Historical Stock Chart
From Apr 2024 to May 2024
Venture Life (LSE:VLG)
Historical Stock Chart
From May 2023 to May 2024